After the targeted drugs are marketed, they need the approval of the National Medical Insurance Bureau to apply for medical insurance drugs, and the time is about 1-2 years.
In 2023, three targeted drugs for lung cancer entered the medical insurance list, namely Butinib, Rollatinib and Sevotinib.